Table 2.

Group averaged diseased-to-normal parameter ratios: mean ± SD and (skewness).

Disease group	r1	r2	r3	1/c1	1/c2
ALS (21,148)*	1.0±0.2 (−0.01)	1.8±1.2 (1.9)	1.3±0.7 (2.9)	1.8±1.3 (2.7)	1.4±0.9 (2.7)
Radiculopathy(10, 62)	1.0±0.2 (1.6)	1.2±0.5 (1.7)	1.1±0.3 (0.8)	1.2±0.5 (1.5)	1.2±0.5 (2.6)
Poly/dermatoa (13,37)	1.0±0.3 (0.5)	1.6±1.1 (2.3)	1.2±0.7 (2.4)	1.8±1.5 (1.7)	1.5±1.2 (2.7)
CMTb (4,30)	1.3±0.4 (2)	4.9±4.8 (2)	1.9±0.9 (0.6)	4.9±4.1 (1.7)	2.9±2.2 (1.2)
IBMc (4,39)	0.96±0.2 (0.89)	1.9±1.2 (2.3)	1.1±0.6 (0.7)	2.4±1.7 (1.6)	1.6±1.1 (2.2)
Myotonic Dystrd (3,10)	0.94±0.2 (0.55)	3.4±1.8 (0.7)	2.0±0.84 (0.6)	3.8±2.2 (0.5)	2.8±1.7 (0.3)
FSHDe (3,17)	1.3±0.3 (0.07)	2.0±1.1 (1.1)	1.5±0.86 (1.9)	1.8±1.0 (1.0)	1.8±1.1 (1.9)
Othermyopathyf (5,15)	0.99±0.2 (0.9)	2.6±2.3 (1.2)	1.6±1.2 (1.6)	2.1±1.9 (1.5)	2.3±2.6 (1.7)
“ neuropathyf (5,31)	1.1±0.3 (.01)	1.9±2.3 (2.6)	1.4±0.9 (1.4)	1.6±1.5 (2.7)	1.9±2.1 (2.6)
p-values (and sides) g	0.2 (2 sided)	0.0035 (1)	0.0016 (1)	0.0043 (1)	0.0008 (1)

^*(the number of patients, and the number of muscles examined, including lefts, rights, and repeat measurements)

^aPolymyositis and dermatomyositis combined

^bCharcot-Marie-Tooth disease

^cInclusion body myositis

^dMyotonic Dystrophy

^eFacioscapulohumeral muscular dystrophy

^fsee section 4.7

^gNominal t-test values for null hypothesis ratio = 1; cf section 5.1